PE20211586A1 - Composicion y metodo para el ahorro de opioides - Google Patents
Composicion y metodo para el ahorro de opioidesInfo
- Publication number
- PE20211586A1 PE20211586A1 PE2020002272A PE2020002272A PE20211586A1 PE 20211586 A1 PE20211586 A1 PE 20211586A1 PE 2020002272 A PE2020002272 A PE 2020002272A PE 2020002272 A PE2020002272 A PE 2020002272A PE 20211586 A1 PE20211586 A1 PE 20211586A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- opioids
- approximately
- weight
- saving
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 229940005483 opioid analgesics Drugs 0.000 title abstract 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 abstract 3
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 abstract 3
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 abstract 3
- 229950011318 cannabidiol Drugs 0.000 abstract 3
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 abstract 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract 3
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 abstract 3
- 229960004242 dronabinol Drugs 0.000 abstract 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003505 terpenes Chemical class 0.000 abstract 2
- 235000007586 terpenes Nutrition 0.000 abstract 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 abstract 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 abstract 1
- -1 A-terpinene Chemical compound 0.000 abstract 1
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 abstract 1
- 241000218236 Cannabis Species 0.000 abstract 1
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 abstract 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 abstract 1
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 abstract 1
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 abstract 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 abstract 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 abstract 1
- 229960000240 hydrocodone Drugs 0.000 abstract 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 abstract 1
- 229930007744 linalool Natural products 0.000 abstract 1
- 229960002085 oxycodone Drugs 0.000 abstract 1
- 229960005118 oxymorphone Drugs 0.000 abstract 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La presente invencion se refiere a una composicion farmaceutica que comprende delta-9-tetrahidrocannabinol (THC), cannabidiol (CBD) y una fraccion de terpenos, dicha composicion farmaceutica comprende un extracto de una planta de Cannabis; el THC se encuentra aproximadamente entre 15 % a 85 % en peso de la composicion; el CBD se encuentra aproximadamente entre 15 % a 40 % en peso de la composicion; la fraccion de terpenos se encuentra aproximadamente entre 0.01 % a 10 % en peso de la composicion seleccionado de B-mirceno, A-terpineno, linalool, entre otros; y adicionalmente comprende uno o ambos de cannabicromeno (CBC) y cannabigerol (CBG); tambien incluye un opioide seleccionado de oxicodona, hidrocodona, oximorfona, entre otros. La composicion es util en el tratamiento de la dependencia y/o adiccion a los opioides.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018100928A AU2018100928A4 (en) | 2018-07-03 | 2018-07-03 | Composition and method for opioid sparing |
| PCT/AU2019/050699 WO2020006598A1 (en) | 2018-07-03 | 2019-07-03 | Composition and method for opioid sparing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211586A1 true PE20211586A1 (es) | 2021-08-18 |
Family
ID=63079660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020002272A PE20211586A1 (es) | 2018-07-03 | 2019-07-03 | Composicion y metodo para el ahorro de opioides |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210290592A1 (es) |
| EP (1) | EP3817734A4 (es) |
| KR (1) | KR20210071941A (es) |
| AU (2) | AU2018100928A4 (es) |
| BR (1) | BR112020027070A2 (es) |
| CA (1) | CA3104741A1 (es) |
| CL (1) | CL2020003373A1 (es) |
| CO (1) | CO2021001057A2 (es) |
| IL (1) | IL279903A (es) |
| MX (1) | MX2021000023A (es) |
| PE (1) | PE20211586A1 (es) |
| SG (1) | SG11202013194VA (es) |
| WO (1) | WO2020006598A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3134108A1 (en) * | 2019-03-21 | 2020-09-24 | ZYUS Life Sciences US Ltd. | Cannabinoid and application supported opioid tapering |
| JP2023529476A (ja) * | 2020-06-12 | 2023-07-10 | ゼリラ セラピューティクス オペレーションズ ピーティーワイ リミテッド | 慢性疼痛を治療するための組成物及び方法 |
| IL309776A (en) * | 2021-07-01 | 2024-02-01 | Ananda Scient Inc | Methods of treating pain using cannabinoids |
| CA3241130A1 (en) | 2022-01-28 | 2023-08-03 | Bastian BAASCH | Method for the production of a plant extract |
| AU2023214140A1 (en) | 2022-01-31 | 2024-07-11 | Vertanical GmbH | Composition comprising delta-9-tetrahydrocannabinol and terpenes |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2965493C (en) * | 2014-10-21 | 2021-12-07 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
| EP3247402A4 (en) * | 2015-01-21 | 2018-08-08 | Willinsky, Michael | Composition and methods to improve stability, dosing, pharmacodynamics and product shelf life of endocannabinoids, phytocannabinoids and synthetic cannabinoids delivered by nasal inhaler |
| WO2018222923A1 (en) * | 2017-05-31 | 2018-12-06 | Phytecs, Inc. | Pharmaceutical compositions comprising cannabidiol and beta-caryophyllene and methods for their use |
| WO2019089558A1 (en) * | 2017-10-30 | 2019-05-09 | Endocanna Health, Inc. | Graphical user interfaces for determining personalized endocannabinoid genotypes and associated recommendations |
-
2018
- 2018-07-03 AU AU2018100928A patent/AU2018100928A4/en active Active
-
2019
- 2019-07-03 BR BR112020027070-9A patent/BR112020027070A2/pt unknown
- 2019-07-03 MX MX2021000023A patent/MX2021000023A/es unknown
- 2019-07-03 KR KR1020217002483A patent/KR20210071941A/ko active Search and Examination
- 2019-07-03 US US17/257,513 patent/US20210290592A1/en active Pending
- 2019-07-03 WO PCT/AU2019/050699 patent/WO2020006598A1/en active Application Filing
- 2019-07-03 AU AU2019297197A patent/AU2019297197A1/en active Pending
- 2019-07-03 SG SG11202013194VA patent/SG11202013194VA/en unknown
- 2019-07-03 CA CA3104741A patent/CA3104741A1/en active Pending
- 2019-07-03 EP EP19829991.9A patent/EP3817734A4/en active Pending
- 2019-07-03 PE PE2020002272A patent/PE20211586A1/es unknown
-
2020
- 2020-12-23 CL CL2020003373A patent/CL2020003373A1/es unknown
- 2020-12-31 IL IL279903A patent/IL279903A/en unknown
-
2021
- 2021-01-29 CO CONC2021/0001057A patent/CO2021001057A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3817734A1 (en) | 2021-05-12 |
| CO2021001057A2 (es) | 2021-06-30 |
| CL2020003373A1 (es) | 2021-08-13 |
| AU2018100928A4 (en) | 2018-08-09 |
| SG11202013194VA (en) | 2021-01-28 |
| AU2019297197A1 (en) | 2021-01-28 |
| CA3104741A1 (en) | 2020-01-09 |
| EP3817734A4 (en) | 2022-03-16 |
| US20210290592A1 (en) | 2021-09-23 |
| IL279903A (en) | 2021-03-01 |
| KR20210071941A (ko) | 2021-06-16 |
| WO2020006598A1 (en) | 2020-01-09 |
| MX2021000023A (es) | 2021-05-27 |
| BR112020027070A2 (pt) | 2021-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211586A1 (es) | Composicion y metodo para el ahorro de opioides | |
| PE20200676A1 (es) | Composicion de cannabis | |
| PE20230607A1 (es) | Composicion de cannabis | |
| IN2014DN09507A (es) | ||
| CO2019013887A2 (es) | Composiciones y tratamientos para el trastorno del sueño | |
| NZ735216A (en) | Oral solid cannabinoid formulations, methods for producing and using thereof | |
| CO2017008437A2 (es) | Métodos de purificación de cannabinoides, composiciones y kits de los mismos | |
| MX2020007784A (es) | Uso de cannabinoides en el tratamiento de la epilepsia. | |
| CL2020003368A1 (es) | Composicion y metodo para tratar el dolor | |
| CL2019000474A1 (es) | Composiciones solubles al agua que comprenden cannabinoides purificados. | |
| CO2019002123A2 (es) | Plantas y métodos para aumentar y disminuir la síntesis de cannabinoides | |
| CO6290695A2 (es) | Uso de canabinoides en combinación con un medicamento antisicótico. | |
| GB201116789D0 (en) | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd) | |
| CL2019000198A1 (es) | Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración. | |
| AR113749A1 (es) | Formulaciones cannabinoides sintéticas y a base de plantas de inicio rápido y acción prolongada | |
| CL2019000270A1 (es) | Composición de cannabis. | |
| MX2021005476A (es) | Plantas de cannabis con un perfil de cannabinoides enriquecidas con ¿-9-tetrahidrocannabinol y cannabigerol. | |
| CO2020009747A2 (es) | Métodos para purificar cannabinoides usando cromatografía líquido-líquido | |
| PE20200383A1 (es) | Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados | |
| ECSP21075073A (es) | Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicoactivos | |
| CO2021001059A2 (es) | Composición de cannabinoides y método para tratar el ptsd y/o la ansiedad | |
| MX2020004232A (es) | Composiciones de cannabinoides y sus metodos de uso. | |
| GB201120067D0 (en) | Phytocannabinoids for use in the treatment of intestinal inflammatory diseases | |
| CO2020001342A2 (es) | Composición que contiene cannabinoides con biodisponibilidad mejorada | |
| CL2011000722A1 (es) | Composicion farmaceutica en forma de unguento estable al almacenamiento, que comprende: a) un compuesto de vitamina d, b) un corticosteroide y c) un compuesto alquilamino sustituido, en un vehiculo de petrolato que opcionalmente contiene aceite mineral, tocoferol o una combinacion de ellos; uso en tratamiento de la psoriasis. |